Vaxart Inc

Vaxart Inc (VXRT)

$8.99
0.77 (+9.37%)
Neutral
Symbol VXRT
Price 8.99$
Beta -0.203
Volume Avrg. 34.84M
Market Cap 1.04B
Shares (2019) 21,569.52K
Last Div 0
Dividend Yield -
DCF Unlevered 28.31 Strong Buy
DCF Levered 25.15 Strong Buy
ROE -143.95% Strong Sell
ROA -50.35% Strong Sell
Operating Margin -161.07% Strong Sell
Debt / Equity 185.92% Buy
P/E -0.84
P/B 1.22 Strong Buy

Retained Earning Schedule

Year 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2019
Retained Earnings (Previous Year) -170-206-224-224--79-90-109-134-80-98
Net Income -19-191-5-9-11-19-25-10-18-19
Stock Dividends -17---0-70---64--0
Dividend Paid -----------
Retained Earnings -206-224-224-228-79-90-109-134-80-98-117

PPE Schedule

Year 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2019
Gross PPE 2111-420011
Annual Depreciation -1-0-0-15-2-20112
Capital Expenditure -0--0--1-0-0-0-0-1-1
Net PPE 11104200112

Intangible and Goodwill Schedule

Year 2008 2009 2010 2011 2013 2014 2015 2016 2017 2018 2019
Intangible and Goodwill (Previous Year) -----1---019
New Purchases -24-91-140-12--10-18-15--1-
Intangible and Goodwill ----1---01917

About


Dr. Wouter Latour
Healthcare
Biotechnology
NASDAQ Capital Market

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. The company is headquartered in South San Francisco, California and currently employs 28 full-time employees. The firm has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. The company has preclinical RSV non-fusion inhibitor program. The company has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.